Ranbaxy

Introduction Ranbaxy Laboratories Limited is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines. Ranbaxy is ranked amongst the top ten global generic companies and has a presence in 23 of the top 25 pharma markets of the world. The company is headquartered in India. It has presence in 49 countries, with manufacturing facilities in 11 and a diverse product portfolio. It’s a public ltd company. Ranbaxy exports its products to 125 countries with ground operations in 46 and manufacturing facilities in seven countries. The CEO of the company is Malvinder Mohan Singh.

Company Profile Type: Public Ltd Founded : 1961 Headquarters: Gurgaon, Haryana, India Industry: Pharmaceutical Websites: www.ranbaxy.com

History

Ranbaxy was started by Ranjit Singh and Gurbax Singh in 1937 as a distributor for a Japanese company Shionogi. Interestingly the name Ranbaxy is a portmanteau word from the names of its first owners Ranjit and Gurbax. Bhai Mohan Singh bought the company in 1952 from his cousins Ranjit Singh and Gurbax Singh. After Bhai Mohan Singh's son Parvinder Singh joined the company in 1967, the company saw a significant transformation in its business and scale. In 1998, Ranbaxy entered United States, the world’s largest pharmaceutical market and now the biggest market for Ranbaxy, accounting for 28% of Ranbaxy's sales in 2005. Ranbaxy is also one of the world's top 10 in that pharmaceutical category as well. Yet, with India's agreement to apply international patent law at the beginning of 2005, Ranbaxy has begun converting itself into a full-fledged research-based pharmaceutical company. A major part of this effort has been the establishment of the company's own research and development center, which has enabled the company to begin to enter the new chemical entities (NCE) and novel drug delivery systems (NDDS) markets. In the mid-2000s, the company had a number of NCEs in progress, and had already launched its first NDDS product, a single daily dosage formulation of ciprofloxacin. Ranbaxy is a truly global operation, producing its pharmaceutical preparations in manufacturing facilities in seven countries, supported by sales and marketing subsidiaries in 44 countries, reaching more than 100 countries throughout the world. The Company has clocked sales of USD 286 Mn (2006) registering a growth of over 17%. Growing ahead of the market the Company has enhanced its competitive position in the domestic market through its focused approach. Ranbaxy views its R&D capabilities as a vital component of its business strategy that will provide the company with a sustainable, long-term competitive advantage. The robust R&D environment within the company for both drug discovery & development and for generics is designed to bring into sharper focus, the unique needs of both equally.

Public Relation Activities:

Direct marketing

Public relations

Advertising

Catalogues Mailings Telemarketing Electronic shopping TV shopping Free samples

Speeches Seminars Annual reports Charitable donations Sponsorships Publications Public interest articles in media

Print and broadcast ads Packaging Brochures and booklets Posters and leaflets Display signs Audio visual Symbols and logos

Media Relations 1) Two day Executive Workshop on “ Intellectual Property Rights – Imperatives for the Knowledge Economy” 2) Fashion Show & Textile Exhibition – Department of Textile Technology 3)Launching of First Guide of SWEP 4) Ads on Television ,radio, newspaper, magazines, hoardings etc.

Ranbaxy's Future Plans Ranbaxy Laboratories has not only reemerged on the horizon today with its new corporate identity as SRL-Ranbaxy, Clinical Reference Laboratories,

but also today announced ambitious expansion plan aiming at a turnover of Rs. 450 crores by 2009 in pathology testing. Briefing the media on their future plans, Malvinder Mohan Singh, and Shivender Mohan Singh, promoters of Ranbaxy, said earlier their focus was on the health care sector with particular emphasis on health care delivery but now, with the new acquisition, they were entering the laboratory testing business in a big way as SLR-Ranbaxy has both strong quality culture and technological expertise. It has the potential to fully exploit opportunities for growth in the clinical testing areas as it happens to be the single largest source of clinical laboratory testing in South Asia offering an extensive range of diagnostic tests. With the backing of four full-fledged testing facilities in Mumbai, Delhi, Mohali and Banglore, the company plans to increase its presence from 215 to over 400 towns with the number of collection centres going up from the existing 500 to 2,000 across the country. As these centres would be connected with the laboratories' network, the delivery of the results of the diagnostic tests would be much faster, depending, of course, on the minimum time taken in conducting the tests. He said the clinical reference laboratory today was developing and providing incisive diagnostic, prognostic and monitoring tests and services of the highest quality to doctors and patients. It had first class facilities in India to have accreditation from NABL in 1998.. It aimed at upgrading and developing the market utilising the world gold standards by using incisive technology and services to provide accurate solutions with ethical standards and care as its core value. The laboratory which conducted four million tests at present would have the capacity to carry out 25 million tests annually. The company would provide services of worldclass tests at affordable prices in the country.

Key strengths

1) Leadership in Novel Drug Delivery System (NDDS) products, which

offer value-added differentiation over conventional products. Key brands include Cifran OD (Ciprofloxacin), Zanocin OD (Ofloxacin) & Sporidex AF 2) Strong brand building capabilities, reflected in the fact that 20 brands feature in the 300 brands of the Industry” list. The leading 5 brands are Sporidex (Cephalexin), Cifran (Ciprofloxacin), Mox (Amoxycillin), Zanocin (Ofloxacin) & Volini 3) A well-built customer interface, with one of the highest customer coverage across India, and an excellent franchise with both Generalists & Specialists. This is proven by Ranbaxy India’s Corporate Image being perceived as ‘Best-in-Class’ by customer 4) Great emphasis is placed on Knowledge Management and Medicomarketing initiatives such as Advisory Board Meetings, Post Marketing Surveillance Studies and Continuous Medical Education programs. These have resulted in an excellent customer relationship with the medical fraternity. More than 2000 interface programs (Symposia, CME’s) are conducted and about 20 Clinical Papers published anually

Mission & Values 1) 2) 3) 4) 5)

To become Research Based International Pharmaceutical Company Provide products & service of highest quality Ensure profitable growth & enhance wealth of the shareholders Manage operations with high concern for safety and environment Be responsible corporate citizen

Aspirations by 2012 1) Aspire to $5 billion company 2) Become a top 5 global generic player 3) Significant income from proprietary pro

Corporate Image As a global leader in pharmaceuticals we take pride not only in providing products that enable people to live healthier and fuller lives, but also in giving back to the society.At Ranbaxy, Corporate Social Responsibility and concern for Environment, Health and Safety are a part of the corporate DNA. As a global leader in pharmaceuticals we take pride not only in providing products that enable people to live healthier and fuller lives, but also in giving back to the society. Being an innovation led pharmaceutical company, we encourage scientific endeavours through Ranbaxy Science Foundation that offers annual Research Awards aimed at recognizing and rewarding excellence in original research work. Ranbaxy Community Health Care Society (RCHS), the Company's apex CSR vehicle, provides free integrated healthcare at the doorstep of about 175000 people in 83 villages, largely identified as 'unserved'. Ranbaxy today offers a range of curative, preventive and health promotive services, ably supported by laboratory facilities covering areas of maternal child health, family planning, adolescent health, reproductive health and health education including AIDS awareness. The Services are delivered through six well-equipped mobile healthcare vans operating in the Indian states of Punjab, Haryana, Himachal Pradesh and Madhya Pradesh. During the year, community health was monitored through regular mobile field clinics and home visits. The twilight (old) areas witnessed a further reduction in the Birth Rate (BR) and Infant Mortality Rates (IMR) and no maternal death was reported. In the intensive (new) areas too, IMR showed a further decline and the Maternal Mortality Rate (MMR) came down to nil, although there was not much change in the Birth Rate.

These activities have helped Wipro build a very strong corporate image.

Presented By: Sumit B. Shetty SY BMS 48